PARP inhibitor-based first-line maintenance therapy for newly diagnosed advanced ovarian cancer across molecular subgroups: an updated systematic review and network meta-analysis

Juntao Feng, Xiaomei Qin, Xiaoliang Mo · 2026

Read PARP inhibitor-based first-line maintenance therapy for newly diagnosed advanced ovarian cancer across molecular subgroups: an updated systematic review and network meta-analysis by Juntao Feng, Xiaomei Qin, Xiaoliang Mo (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13630527.txt.

Description

Juntao Feng and co-authors update a systematic review and network meta-analysis of PARP inhibitor maintenance therapy for advanced ovarian cancer. Their paper deals with first-line care after a new finding.

PARP inhibitor maintenance is now central to first-line treatment, and choice among options depends on BRCA mutation and homologous recombination deficiency status. Recent guidance stresses marker-directed care, but head-to-head evidence across subgroups is limited. The team searched major libraries and meeting work for controlled trials in late-stage epithelial ovarian, fallopian tube, or primary peritoneal cancer. Their network analysis weighs efficacy and safety of the upkeep strategies.

Catalog record

CREATORJuntao Feng, Xiaomei Qin, Xiaoliang Mo
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE44 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13630527

Browse the full library · About the Tower of Babel